What drugs modify the risk of iatrogenic impulse-control disorders in Parkinson’s disease? A preliminary pharmacoepidemiologic study

Autoři: Nakyung Jeon aff001;  Marco Bortolato aff002
Působiště autorů: College of Pharmacy, Chonnam National University, Gwang-ju, Republic of Korea aff001;  Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, Utah, United States of America aff002
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0227128



Parkinson’s disease (PD) patients treated with pramipexole (PPX) and ropinirole (ROP) exhibit a higher risk of developing impulse control disorders (ICDs), including gambling disorder, compulsive shopping, and hypersexuality. The management of ICDs in PD is challenging, due to the limited availability of effective therapeutic alternatives or counteractive strategies. Here, we used a pharmacoepidemiological approach to verify whether the risk for PPX/ROP-associated ICDs in PD patients was reduced by drugs that have been posited to exert therapeutic effects on idiopathic ICDs–including atypical antipsychotics (AAs), selective serotonin reuptake inhibitors (SSRIs), and glutamatergic modulators (GMs).


To quantify the strength of the associations between PPX/ROP and other medications with respect to ICD risk, odds ratios (ORs) were calculated by multivariable logistic regression, adjusting for age, gender, marital status race, psychiatric comorbidities, and use of cabergoline and levodopa.


A total of 935 patients were included in the analysis. Use of GMs, SSRIs, and AAs was not associated with a decreased ICD risk in PD patients treated with PPX/ROP; conversely, ICD risk was significantly increased in patients treated with either GMs (Adjusted Odds Ratio, ORa: 14.00 [3.58–54.44]) or SSRIs (ORa: 3.67 [1.07–12.59]). Results were inconclusive for AAs, as available data were insufficient to compute a reliable ORa.


These results suggest that some of the key pharmacological strategies used to treat idiopathic ICD may not be effective for ICDs associated with PPX and ROP in PD patients. Future studies with larger cohorts are needed to confirm, validate, and extend these findings.

Klíčová slova:

Antipsychotics – Depression – Diagnostic medicine – Dopamine – Drug research and development – Drug therapy – Levodopa – Parkinson disease


1. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: A cross-sectional study of 3090 patients. Arch Neurol [Internet]. 2010 May 1 [cited 2019 Apr 4];67(5):589–95. Available from: http://archneur.jamanetwork.com/article.aspx?doi=10.1001/archneurol.2010.65 20457959

2. Molde H, Moussavi Y, Kopperud ST, Erga AH, Hansen AL, Pallesen S. Impulse-control disorders in Parkinson’s Disease: A meta-analysis and review of case-control studies. Front Neurol. 2018 May;9(MAY):330.

3. Holloway RG. Pramipexole vs levodopa as initial treatment for Parkinson Disease: A 4-year randomized controlled trial. Arch Neurol [Internet]. 2004 Jul 1 [cited 2019 Apr 23];61(7):1044–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15262734 doi: 10.1001/archneur.61.7.1044 15262734

4. Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F. Ropinirole versus bromocriptine in the treatment of early Parkinson’s disease: A 6-month interim report of a 3-year study. Mov Disord [Internet]. 1998 Jan 1 [cited 2019 Apr 23];13(1):46–51. Available from: http://doi.wiley.com/10.1002/mds.870130112 9452325

5. Weddle KE, Guo JJ, Wigle PR, Ajayi FO. Assocation between impulse control disorders and the use of dopamine agonists. Pharmacoepidemiol Drug Saf [Internet]. 2011;20(PG-S196-S197):S196–7. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L70665300 NS -

6. Aguirre C, García M, Lertxundi U. Impulsive control disorders associated with dopamine agonists drugs: Analysis of cases reported in the European pharmacovigilance database (eudravigilance). Basic Clin Pharmacol Toxicol [Internet]. 2016;119(PG-40):40. Available from: http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L617433913 NS -

7. Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med [Internet]. 2014 Dec 1 [cited 2019 Apr 4];174(12):1930–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25329919 doi: 10.1001/jamainternmed.2014.5262 25329919

8. Marques A, Durif F, Fernagut PO. Impulse control disorders in Parkinson’s disease. J Neural Transm. 2018;125(8):1299–312. doi: 10.1007/s00702-018-1870-8 29511827

9. Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E, et al. Dopamine Agonists and Impulse Control Disorders: A Complex Association. Drug Saf [Internet]. 2018 Jan [cited 2018 Oct 1];41(1):19–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28861870 doi: 10.1007/s40264-017-0590-6 28861870

10. Nirenberg MJ. Dopamine Agonist Withdrawal Syndrome: Implications for Patient Care. Drugs Aging. 2013 Aug;30(8):587–92. doi: 10.1007/s40266-013-0090-z 23686524

11. Vilas D, Pont-Sunyer C, Tolosa E. Impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord [Internet]. 2012 Jan 1 [cited 2019 Apr 26];18:S80–4. Available from: https://www.sciencedirect.com/science/article/pii/S1353802011700268?via%3Dihub doi: 10.1016/S1353-8020(11)70026-8 22166463

12. Kim SW, Grant JE, Adson DE, Shin YC, Zaninelli R. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry [Internet]. 2002 Jun [cited 2019 Apr 16];63(6):501–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12088161 doi: 10.4088/jcp.v63n0606 12088161

13. Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol [Internet]. 2006 Jul [cited 2019 Apr 16];21(4):203–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16687991 doi: 10.1097/00004850-200607000-00002 16687991

14. Coccaro EF, Lee RJ, Kavoussi RJ. A Double-Blind, Randomized, Placebo-Controlled Trial of Fluoxetine in Patients With Intermittent Explosive Disorder. J Clin Psychiatry [Internet]. 2009 May 15 [cited 2019 Apr 16];70(5):653–62. Available from: http://www.psychiatrist.com/abstracts/abstracts.asp?abstract=200905/050903.htm doi: 10.4088/JCP.08m04150 19389333

15. Van den Eynde F, Senturk V, Naudts K, Vogels C, Bernagie K, Thas O, et al. Efficacy of Quetiapine for Impulsivity and Affective Symptoms in Borderline Personality Disorder. J Clin Psychopharmacol [Internet]. 2008 Apr [cited 2019 Apr 26];28(2):147–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18344724 doi: 10.1097/JCP.0b013e318166c4bf 18344724

16. Fong T, Kalechstein A, Bernhard B, Rosenthal R, Rugle L. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav [Internet]. 2008 May [cited 2019 Apr 29];89(3):298–303. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18261787 doi: 10.1016/j.pbb.2007.12.025 18261787

17. Coskun F, Akca OF. Treatment of Intermittent Explosive Disorder With Carbamazepine. Clin Neuropharmacol. 2018 Mar;41(2):82–3. doi: 10.1097/WNF.0000000000000276 29533363

18. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry [Internet]. 2002 Jul [cited 2019 Apr 25];63(7):559–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12143910 doi: 10.4088/jcp.v63n0704 12143910

19. Papay K, Xie SX, Stern M, Hurtig H, Siderowf A, Duda JE, et al. Naltrexone for impulse control disorders in Parkinson disease. Neurology. 2014 Aug;83(9):826–33. doi: 10.1212/WNL.0000000000000729 25037206

20. Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, et al. Multicenter Investigation of the Opioid Antagonist Nalmefene in the Treatment of Pathological Gambling. Am J Psychiatry [Internet]. 2006 Feb [cited 2019 Apr 25];163(2):303–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16449486 doi: 10.1176/appi.ajp.163.2.303 16449486

21. Pettorruso M, De Risio L, Martinotti G, Di Nicola M, Ruggeri F, Conte G, et al. Targeting the Glutamatergic System to Treat Pathological Gambling: Current Evidence and Future Perspectives. Biomed Res Int. 2014;

22. Grant JE, Kim SW, Odlaug BL. N-Acetyl Cysteine, a Glutamate-Modulating Agent, in the Treatment of Pathological Gambling: A Pilot Study. Biol Psychiatry [Internet]. 2007 Sep 15 [cited 2019 Apr 27];62(6):652–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17445781 doi: 10.1016/j.biopsych.2006.11.021 17445781

23. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology [Internet]. 2003 Aug 12 [cited 2019 Apr 26];61(3):422–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12913220 doi: 10.1212/01.wnl.0000076478.45005.ec 12913220

24. Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol [Internet]. 2010 Sep [cited 2019 Apr 26];68(3):400–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20687121 doi: 10.1002/ana.22029 20687121

25. Vittinghoff E, McCulloch CE. Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression. Am J Epidemiol [Internet]. 2007 Jan 12 [cited 2019 May 11];165(6):710–8. Available from: https://academic.oup.com/aje/article-lookup/doi/10.1093/aje/kwk052 17182981

26. Weiss HD, Marsh L. Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease. Neurol Clin Pract [Internet]. 2012 Dec [cited 2019 Apr 24];2(4):267. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23634371 doi: 10.1212/CPJ.0b013e318278be9b 23634371

27. McElroy SL, Pope HG, Keck PE, Hudson JI, Phillips KA, Strakowski SM. Are impulse-control disorders related to bipolar disorder? Compr Psychiatry [Internet]. 1996 Jul 1 [cited 2019 Apr 24];37(4):229–40. Available from: https://www.sciencedirect.com/science/article/pii/S0010440X96900012?via%3Dihub doi: 10.1016/s0010-440x(96)90001-2 8826686

28. Hoptman MJ. Impulsivity and aggression in schizophrenia: a neural circuitry perspective with implications for treatment. CNS Spectr [Internet]. 2015 Jun [cited 2019 Apr 24];20(3):280–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25900066 doi: 10.1017/S1092852915000206 25900066

29. Bidzan L, Bidzan M, Pąchalska M. Aggressive and impulsive behavior in Alzheimer’s disease and progression of dementia. Med Sci Monit. 2012;18(3):CR182–9. doi: 10.12659/MSM.882523 22367129

30. Lejoyeux M, Arbaretaz M, McLoughlin M, Adiès J. Impulse control disorders and depression. J Nerv Ment Dis. 2002;190(5):310–4. doi: 10.1097/00005053-200205000-00007 12011611

31. Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol [Internet]. 2010 Dec [cited 2019 Apr 27];68(6):963–8. Available from: http://doi.wiley.com/10.1002/ana.22164 21154480

32. Walsh RA, Lang AE. Multiple impulse control disorders developing in Parkinson’s disease after initiation of amantadine [Internet]. Vol. 27, Movement Disorders. John Wiley & Sons, Ltd; 2012 [cited 2019 May 15]. p. 326–7. Available from: http://doi.wiley.com/10.1002/mds.23964 21954056

33. Weintraub D, Taraborelli D, Morales KH, Duda JE, Katz IR, Stern MB. Escitalopram for Major Depression in Parkinson’s Disease: An Open-Label, Flexible-Dosage Study. J Neuropsychiatry Clin Neurosci. 2014;18(3):377–83.

34. Dell’Osso B, Hadley S, Allen A, Baker B, Chaplin WF, Hollander E. Escitalopram in the treatment of impulsive-compulsive internet usage disorder: An open-label trial followed by a double-blind discontinuation phase. J Clin Psychiatry. 2008;69(3):452–6. doi: 10.4088/jcp.v69n0316 18312057

35. Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry. 2002;63(1):44–8. doi: 10.4088/jcp.v63n0109 11838625

36. Pes R, Godar SC, Fox AT, Burgeno LM, Strathman HJ, Jarmolowicz DP, et al. Pramipexole enhances disadvantageous decision-making: Lack of relation to changes in phasic dopamine release. Neuropharmacology [Internet]. 2017 Mar 1 [cited 2019 Apr 27];114:77–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27889491 doi: 10.1016/j.neuropharm.2016.11.014 27889491

37. Seeman P. Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015;69(4):183–9. doi: 10.1002/syn.21805 25645960

38. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol [Internet]. 2005 Apr 1 [cited 2019 May 14];58(4):323–37. Available from: https://www.sciencedirect.com/science/article/pii/S0895435604002987 doi: 10.1016/j.jclinepi.2004.10.012 15862718

39. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry [Internet]. 2004 Jan [cited 2019 May 14];75(1):141–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14707325 14707325

40. Biundo R, Weis L, Abbruzzese G, Calandra-Buonaura G, Cortelli P, Jori MC, et al. Impulse control disorders in advanced Parkinson’s disease with dyskinesia: The ALTHEA study. Mov Disord. 2017;32(11):1557–65. doi: 10.1002/mds.27181 28960475

41. Schreiber L, Odlaug BL, Grant JE. Impulse control disorders: updated review of clinical characteristics and pharmacological management. Front psychiatry [Internet]. 2011 [cited 2018 Oct 1];2:1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21556272 doi: 10.3389/fpsyt.2011.00001 21556272

42. Molho ES, Factor SA. Parkinson’s disease: The treatment of drug-induced hallucinations and psychosis. Curr Neurol Neurosci Rep. 2001;1(4):320–328. doi: 10.1007/s11910-001-0085-8 11898537

43. Friedman JH. Atypical antipsychotics in the EPS-vulnerable patient. Psychoneuroendocrinology. 2003;28:39–51.

44. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(S3):S42–S80.

45. Burstein ES, Ma J, Wong S, et al. Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther. 2005;315(3):1278–1287 doi: 10.1124/jpet.105.092155 16135699

46. Mizrahi R, Agid O, Borlido C, et al. Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophr Res. 2011;131(1–3):63–68. doi: 10.1016/j.schres.2011.05.005 21684721

47. Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5–12.

48. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson’s disease. Drug Saf. 2003;26(9):643–659. doi: 10.2165/00002018-200326090-00004 12814332

Článek vyšel v časopise


2020 Číslo 1
Nejčtenější tento týden